Buprenorphine and Estazolam: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Estazolam
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines slow down your brain and breathing, and taking them together makes that effect stronger. Buprenorphine is an opioid, and estazolam is a benzodiazepine (a sleep and anxiety medicine). When they are combined, they can add up and cause heavy sedation, very slow breathing, and in serious cases, coma or even death.
This is a real concern, so please don't stop either drug on your own, since stopping suddenly can be dangerous too. The good news is your care team can manage this. Talk with your doctor or pharmacist. They may adjust doses, watch you more closely, or explore other options for anxiety or sleep.
Effect: Additive CNS and respiratory depression when buprenorphine (partial opioid agonist) is combined with estazolam (benzodiazepine). Risk includes profound sedation, respiratory depression, coma, and death.
Mechanism: Pharmacodynamic additive CNS depression (neither agent's metabolism drives this). Evidence: probable; epidemiologic data link concomitant CNS depressants with increased overdose mortality in MAT patients. Onset: unspecified.
- Prefer avoiding concurrent use; taper the benzodiazepine or use lowest effective dose.
- If combined, monitor mental status and respiratory status; manage cautiously.
- Consider alternatives for anxiety/insomnia.
- Do not withhold MAT solely due to CNS depressant use.
What happens
An increased risk of CNS depression and respiratory depression
Interaction Deep Dive
When buprenorphine is given together with a benzodiazepine, the combined CNS depressant effects can add up, raising the likelihood of respiratory depression, deep sedation, coma, and death. Discontinuing benzodiazepines or other CNS depressants is favored rather than using them at the same time. Managing the patient in a higher level of care or performing a taper may be suitable in certain situations. In others, it may be appropriate to slowly wean the patient off a prescribed benzodiazepine or other CNS depressant, or to reduce the dose to the lowest one that remains effective. Should concurrent use be required, watch for respiratory depression and proceed with caution in management1. A Swedish epidemiological study found that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also took benzodiazepines or other CNS depressants (for instance, medications used for insomnia) face a heightened risk of death. Data drawn from aggregate nationwide death certificates spanning 2010 to 2014 indicated that most overdose deaths involving buprenorphine and methadone also involved the concurrent use of a CNS depressant. Whether the risk of overdose death from concomitant CNS depressant drugs varied between buprenorphine and methadone has not been established 3.
Why it happens (mechanism)
Additive CNS depression
How to manage this interaction
Keep taking both exactly as prescribed unless your care team tells you otherwise. Stopping a benzodiazepine suddenly can be harmful, and medication-assisted treatment should not be withheld.
Here is what your care team may do:
- Adjust doses to the lowest effective amount, individualized for you.
- Monitor you more closely for heavy drowsiness or slow, shallow breathing.
- Consider a gradual taper of the benzodiazepine or an alternative treatment for anxiety or sleep.
Get help right away if you notice extreme sleepiness, confusion, slow breathing, or trouble waking. Ask your pharmacist or doctor before making any changes.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) A Swedish epidemiological study found that patients receiving methadone- or buprenorphine-based medication-assisted treatment (MAT) together with benzodiazepines or other CNS depressants (for example, drugs used to treat insomnia) have an increased risk of death. From July 1, 2005 to December 31, 2012, investigators examined the risk of fatal overdose, non-overdose related mortality, and all-cause mortality by comparing periods when CNS depressants were prescribed with periods without CNS depressant therapy among MAT patients (aged 18 to 50). The findings showed a raised risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01) with combined MAT and benzodiazepine treatment; however, these data were not deemed statistically significant. Although the results indicated an elevated risk of fatal overdose, non-overdose mortality, and all-cause mortality during periods when MAT and non-benzodiazepines were coadministered, only the fatal overdose and all-cause mortality data reached statistical significance; HR 2.34 (95% CI, 1.37 to 3.99) and HR 1.33 (95% CI, 1.12 to 2.45), respectively. The authors did not compare the benzodiazepine cohort with the non-benzodiazepine cohort because they did not adjust for the indication of use for the drugs 3.
b) According to an analysis of aggregate nationwide death certificate data spanning 2010 to 2014, 3495 drug overdose deaths were reported in 2014. Methadone and other CNS depressants were commonly cited as contributors to those deaths. Concurrent alprazolam use was noted in 18.1% of cases, followed by oxycodone (10.1%), cocaine (9.6%), heroin (9%), and diazepam (6.6%). The FDA reported 322 drug overdose deaths in 2014 involving buprenorphine. Among these 322 deaths, 32.9% involved alprazolam, 17.4% involved clonazepam, 11.2% involved diazepam, 11.2% involved heroin, and 9.9% involved fentanyl. The absolute number of methadone-involved deaths was 10 times the number of buprenorphine-involved deaths, although confounding factors and differences in drug utilization were not taken into account. Whether the risk of overdose death with concomitant CNS depressant drugs differed between buprenorphine and methadone is unknown 3.
Common questions
Can I take Buprenorphine and Estazolam together?
Combining buprenorphine and estazolam adds up their sedating effects and can dangerously slow breathing, so use them together only under close medical supervision and never stop either one on your own. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Estazolam interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Estazolam interaction managed?
Keep taking both exactly as prescribed unless your care team tells you otherwise. Stopping a benzodiazepine suddenly can be harmful, and medication-assisted treatment should not be withheld. Here is what your care team may do: Adjust doses to the lowest effective amount, individualized for you. Monitor you more closely for heavy drowsiness or slow, shallow breathing. Consider a gradual taper of th… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Estazolam need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: SUBUTEX(R) sublingual tablets, buprenorphine sublingual tablets. Indivior Inc (per FDA), North Chesterfield, VA, 2021. DailyMed
- US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
Keep reading about Buprenorphine
Keep reading about Estazolam
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist